Investigational drug · Phase 2
FMC-376
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "FMC-376"
First trial start
2024
Feb 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FMC-376", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors With KRAS G12C Mutations
- Solid Tumor, Adult
- Unresectable Solid Tumor
- Metastatic Solid Tumor
- Non Small Cell Lung Cancer
- KRAS G12C
- Locally Advanced Solid Tumor
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "FMC-376" as an intervention, largest first.
Frontier Medicines CorporationIndustry
NCT06244771 · 293 participants (planned) · Start Feb 12, 2024 · Primary completion Oct 2027
Drug: FMC-376 · For: Advanced Solid Tumors With KRAS G12C Mutations; Solid Tumor, Adult; Unresectable Solid Tumor and 3 more
Sites: La Jolla, California; Orange, California; San Francisco, California · 26 sites in all
- Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid TumorsNot yet recruiting
Frontier Medicines CorporationIndustry
NCT07944092 · 282 participants (planned) · Start Dec 2026 · Primary completion Jan 2029
Drug: FMC-242; Trastuzumab (or biosimilar) and 3 more · For: Locally Advanced Solid Tumor
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.